TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease
June 09, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., June 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced results from its collaboration with the Walter and Eliza Hall Institute of Medical...
TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting
May 28, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 28, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized placebo controlled clinical study of SHAPE...
TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)
May 27, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 27, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that, based upon data from its Phase 1b study of birinapant in combination with...
TetraLogic to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference
May 08, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 8, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Bank...
TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual Society of Investigative Dermatology Meeting
May 05, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., May 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized, placebo-controlled clinical study of SHAPE...
TetraLogic to Present at the Deutsche Bank 39th Annual Healthcare Conference
April 30, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 30, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant
April 09, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in a forthcoming issue of the Journal of Medicinal Chemistry of...
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.
April 07, 2014 16:05 ET
|
TetraLogic Pharmaceuticals
SHAPE, a novel, tissue-targeted topical HDAC inhibitor, is expected to enter Phase 2 trials for early-stage CTCL
Encouraging responses seen in a randomized Phase 1 trial after only 28 days of...
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
April 01, 2014 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., April 1, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further...
TetraLogic to Present at the 13th Annual Needham Healthcare Conference
March 31, 2014 07:30 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., March 31, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...